Journal of Clinical Oncology, Vol 19, Issue 22
(November), 2001: 4216-4223
© 2001 American Society for Clinical Oncology
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
By Edith A. Perez,
Charles L. Vogel,
David H. Irwin,
Jeffrey J. Kirshner,
Ravi Patel
From the Mayo Clinic, Jacksonville; Columbia Cancer Research Network, Aventura, FL; Alta Bates Comprehensive Cancer Center, Berkeley; Comprehensive Blood and Cancer Center, Bakersfield, CA; and Hematology/Oncology Associates of Central New York, Syracuse, NY.
Address reprint requests to Edith A. Perez, MD, Division of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224; email: perez.edith{at}mayo.edu
PURPOSE: We evaluated the safety and efficacy of weekly paclitaxel therapy in women with metastatic breast cancer in a phase II multicenter trial. Entry criteria were relatively liberal to reflect the heterogeneity of metastatic breast cancer in clinical practice.
PATIENTS AND METHODS: Patients had histologically confirmed and measurable metastatic breast cancer. Up to two prior chemotherapy regimens for metastatic disease, including prior therapy with anthracyclines and taxanes and prior high-dose therapy, were allowed. Paclitaxel 80 mg/m2 was administered weekly for 4 weeks per 4-week cycle.
RESULTS: We enrolled 212 patients; 211 were assessable for toxicity and 177 were assessable for response. Ninety percent of patients had received prior chemotherapy (adjuvant, metastatic, or both), 46% of patients had three or more involved metastatic sites, and 60% of patients had visceral-dominant disease. Responses were documented on two occasions and were independently reviewed. The overall response rate (complete plus partial response) was 21.5% (95% confidence interval, 15.4% to 27.5%), with 41.8% of patients having disease stabilization. Median time to progression was 4.7 months, and overall survival in all 212 patients enrolled was 12.8 months. Therapy was well tolerated, with a 15% incidence of grade 3/4 hematologic toxicity and a 9% incidence of grade 3 neurotoxicity; other serious toxicities were rare. The response rate and toxicity profile in the 34% of patients  65 years of age were similar to that of younger patients.
CONCLUSION: Weekly paclitaxel therapy was well tolerated and demonstrated reasonable activity in this relatively heavily pretreated population with advanced disease. Further study of weekly paclitaxel in combination therapy is warranted.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
W. J. Kostler, C. C. Zielinski, and on behalf of the Central European Cooperative Onco
Reply to Third consensus on medical treatment of metastatic breast cancer
Ann. Onc.,
March 1, 2010;
21(3):
665 - 666.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. Sikov, D. S. Dizon, R. Strenger, R. D. Legare, K. P. Theall, T. A. Graves, J. S. Gass, T. A. Kennedy, and M. A. Fenton
Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study
J. Clin. Oncol.,
October 1, 2009;
27(28):
4693 - 4700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Stubblefield, H. J. Burstein, A. W. Burton, C. M. Custodio, G. E. Deng, M. Ho, L. Junck, G. S. Morris, J. A. Paice, S. Tummala, et al.
NCCN Task Force Report: Management of Neuropathy in Cancer
J Natl Compr Canc Netw,
September 1, 2009;
7(Suppl_5):
S-1 - S-26.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Moreno-Aspitia and E. A. Perez
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Mayo Clin. Proc.,
June 1, 2009;
84(6):
533 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Roy, B. R. LaPlant, G. G. Gross, C. L. Bane, F. M. Palmieri, and for the North Central Cancer Treatment Group
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane(R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
Ann. Onc.,
March 1, 2009;
20(3):
449 - 453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Gonzalez-Angulo and G. N. Hortobagyi
Optimal Schedule of Paclitaxel: Weekly Is Better
J. Clin. Oncol.,
April 1, 2008;
26(10):
1585 - 1587.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Seidman, D. Berry, C. Cirrincione, L. Harris, H. Muss, P. K. Marcom, G. Gipson, H. Burstein, D. Lake, C. L. Shapiro, et al.
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
J. Clin. Oncol.,
April 1, 2008;
26(10):
1642 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Vu, S. Ellard, C. H. Speers, S. C. M. Taylor, M. L. de Lemos, F. Hu, K. Kuik, and I. A. Olivotto
Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation
Ann. Onc.,
March 1, 2008;
19(3):
461 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Verma and M. Clemons
First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy
Oncologist,
July 1, 2007;
12(7):
785 - 797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ilson, R. Wadleigh, L. Leichman, and D. Kelsen
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer
Ann. Onc.,
May 1, 2007;
18(5):
898 - 902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, V Heinemann, J Jassem, W. Kostler, M Krainer, et al.
Second consensus on medical treatment of metastatic breast cancer
Ann. Onc.,
February 1, 2007;
18(2):
215 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Blum, E. C. Dees, A. Chacko, L. Doane, S. Ethirajan, J. Hopkins, R. McMahon, S. Merten, A. Negron, M. Neubauer, et al.
Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer
J. Clin. Oncol.,
September 20, 2006;
24(27):
4384 - 4390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Lichtman, D. Hollis, A. A. Miller, G. L. Rosner, C. A. Rhoades, E. P. Lester, F. Millard, J. Byrd, S. A. Cullinan, D. M. Rosen, et al.
Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762)
J. Clin. Oncol.,
April 20, 2006;
24(12):
1846 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Nyman, K. J. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M. J. Hawkins, and D. D. Von Hoff
Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies
J. Clin. Oncol.,
November 1, 2005;
23(31):
7785 - 7793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Harries, P. Ellis, and P. Harper
Nanoparticle Albumin-Bound Paclitaxel for Metastatic Breast Cancer
J. Clin. Oncol.,
November 1, 2005;
23(31):
7768 - 7771.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. N. Rich and K. M. Hall
Validation and Development of a Predictive Paradigm for Hemotoxicology Using a Multifunctional Bioluminescence Colony-Forming Proliferation Assay
Toxicol. Sci.,
October 1, 2005;
87(2):
427 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Eniu, F. M. Palmieri, and E. A. Perez
Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer
Oncologist,
October 1, 2005;
10(9):
665 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Green, A. U. Buzdar, T. Smith, N. K. Ibrahim, V. Valero, M. F. Rosales, M. Cristofanilli, D. J. Booser, L. Pusztai, E. Rivera, et al.
Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
J. Clin. Oncol.,
September 1, 2005;
23(25):
5983 - 5992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Wasil and S. M. Lichtman
Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly
Oncologist,
September 1, 2005;
10(8):
602 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mielke, A. Sparreboom, S. M. Steinberg, H. Gelderblom, C. Unger, D. Behringer, and K. Mross
Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer
Clin. Cancer Res.,
July 1, 2005;
11(13):
4843 - 4850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand
Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost
Journal of Oncology Pharmacy Practice,
March 1, 2005;
11(1):
21 - 30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Del Mastro, F. Perrone, L. Repetto, L. Manzione, V. Zagonel, L. Fratino, D. Marenco, M. Venturini, E. Maggi, C. Bighin, et al.
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
Ann. Onc.,
February 1, 2005;
16(2):
253 - 258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez, V. J. Suman, N. E. Davidson, P. A. Kaufman, S. Martino, S. R. Dakhil, J. N. Ingle, R. J. Rodeheffer, B. J. Gersh, and A. S. Jaffe
Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
J. Clin. Oncol.,
September 15, 2004;
22(18):
3700 - 3704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez
Carboplatin in Combination Therapy for Metastatic Breast Cancer
Oncologist,
September 1, 2004;
9(5):
518 - 527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Crown, M. O'Leary, and W.-S. Ooi
Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
Oncologist,
June 2, 2004;
9(suppl_2):
24 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Winer, D. A. Berry, S. Woolf, D. Duggan, A. Kornblith, L. N. Harris, R. A. Michaelson, J. A. Kirshner, G. F. Fleming, M. C. Perry, et al.
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
J. Clin. Oncol.,
June 1, 2004;
22(11):
2061 - 2068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Polee, A. Sparreboom, F. A. L. M. Eskens, R. Hoekstra, J. van de Schaaf, J. Verweij, G. Stoter, and A. van der Gaast
A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer
Clin. Cancer Res.,
March 15, 2004;
10(6):
1928 - 1934.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Trauth and L. J. Goldstein
Taxanes in the Adjuvant Treatment of Breast Cancer
J Natl Compr Canc Netw,
April 1, 2003;
1(2):
222 - 231.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. M. Minisini, A. Tosti, A. F. Sobrero, M. Mansutti, B. M. Piraccini, C. Sacco, and F. Puglisi
Taxane-induced nail changes: incidence, clinical presentation and outcome
Ann. Onc.,
February 1, 2003;
14(2):
333 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O'Shaughnessy, C. Twelves, and M. Aapro
Treatment for Anthracycline-Pretreated Metastatic Breast Cancer
Oncologist,
December 1, 2002;
7(90006):
4 - 12.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Spazzapan, D. Crivellari, D. Lombardi, C. Scuderi, M. D. Magri, A. Veronesi, A. Gatti, and E. A. Perez
Nail Toxicity Related to Weekly Taxanes: An Important Issue Requiring a Change in Common Toxicity Criteria Grading?
J. Clin. Oncol.,
November 1, 2002;
20(21):
4404 - 4405.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Loesch, N. Robert, L. Asmar, M. A. Gregurich, M. O'Rourke, S. Dakhil, and E. Cox
Phase II Multicenter Trial of a Weekly Paclitaxel and Carboplatin Regimen in Patients With Advanced Breast Cancer
J. Clin. Oncol.,
September 15, 2002;
20(18):
3857 - 3864.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Boasberg
Medical Oncology Analysis
Integr Cancer Ther,
June 1, 2002;
1(2):
182 - 184.
[PDF]
|
|
|
|
